FLT4 anticorps (Extracellular Domain)

N° du produit ABIN967368

Cet anticorps anti-FLT4 est un anticorps Rat Monoclonal détectant FLT4 dans IHC (p) et IHC (fro). Adapté pour Souris. Ce Primary Antibody a été cité dans 2+ publications.

Aperçu rapide pour FLT4 anticorps (Extracellular Domain) (ABIN967368)

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp FLT4 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Clone: AFL4

Détail du produit anti-FLT4 anticorps

Épitope: Extracellular Domain

Marque: BD Pharmingen™

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
3. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
4. Please refer to us for technical protocols.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: VEGFR-3 extracellular domain

Isotype: IgG2a kappa

Information d'application

Indications d'application: Immunohistochemistry:
The AFL4 antibody, specific for mouse VEGFR-3, is tested for immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed and formalin-fixed, paraffin-embedded sections. Antigen retrieval with Retrievagen A is recommended for formalin-fixed, paraffin sections. Tissues tested were mouse spleen, liver, kidney, lung and small intestine. The antibody stains endothelial cells of lymphatic vessels. The isotype control recommended for use with this antibody is purified rat IgG2akappa. For optimal indirect immunohistochemical staining, the AFL4 antibody should be titrated (1:10 to 1:50 dilution) and visualized via a three-step staining procedure in combination with polyclonal, biotin conjugated anti-rat Igs (multiple adsorbed) as the secondary antibody and Streptavidin-HRP together with the DAB Detection System. More conveniently, the Anti-Rat Ig HRP Detection Kit, which contains the biotinylated secondary antibody, antibody diluent, streptavidin-HRP and DAB substrate, can be used for staining.

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Aqueous buffered solution containing BSA, goat serum, and ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C.

Références pour anticorps anti-FLT4 (ABIN967368)

Stacker, Caesar, Baldwin, Thornton, Williams, Prevo, Jackson, Nishikawa, Kubo, Achen: "VEGF-D promotes the metastatic spread of tumor cells via the lymphatics." dans: Nature medicine, Vol. 7, Issue 2, pp. 186-91, (2001) (PubMed).

Kubo, Fujiwara, Jussila, Hashi, Ogawa, Shimizu, Awane, Sakai, Takabayashi, Alitalo, Yamaoka, Nishikawa: "Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis." dans: Blood, Vol. 96, Issue 2, pp. 546-53, (2000) (PubMed).

Détails sur FLT4

Antigène: FLT4 (Fms-Related Tyrosine Kinase 4 (FLT4))

Autre désignation: VEGFR-3

Sujet: The AFL4 antibody reacts with mouse VEGFR-3, an endothelial-specific receptor tyrosine kinase (RTK) related to VEGF receptors. The immunogen used was the extracellular domain of VEGFR-3, corresponding to nucleotides 45-2354 in the GeneBank L07296. VEGFR-3 is induced in all endothelial cells (EC’s) during early embryogenesis, and its expression eventually disappears from the vascular endothelial cells of adult tissues. VEGFR-3 is constitutively expressed in the adult lymphatic endothelium. Although VEGFR-3 is not expressed in adult blood vessels, it is induced in vascular endothelial cells of tumor-bearing tissues. Studies have shown that both VEGF-C and VEGF-D, ligands for VEGFR-3, promote lymphatic vessel proliferation throughout central tumor areas and at their peripheries, demonstrating that such molecules aid in the spread of tumor cells from the primary tumor to local lymph nodes.

Pathways: Signalisation RTK, Signaling Events mediated by VEGFR1 and VEGFR2, VEGF Signaling